title: The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.
abstract: The many improvements in breast cancer therapy in recent years have so lowered rates of recurrence that it is now difficult or impossible to conduct adequately powered adjuvant clinical trials. Given the many new drugs and potential synergistic combinations, the neoadjuvant approach has been used to test benefit of drug combinations in clinical trials of primary breast cancer. A recent FDA-led meta-analysis showed that pathologic complete response (pCR) predicts disease-free survival (DFS) within patients who have specific breast cancer subtypes. This meta-analysis motivated the FDA's draft guidance for using pCR as a surrogate endpoint in accelerated drug approval. Using pCR as a registration endpoint was challenged at ASCO 2014 Annual Meeting with the presentation of ALTTO, an adjuvant trial in HER2-positive breast cancer that showed a nonsignificant reduction in DFS hazard rate for adding lapatinib, a HER-family tyrosine kinase inhibitor, to trastuzumab and chemotherapy. This conclusion seemed to be inconsistent with the results of NeoALTTO, a neoadjuvant trial that found a statistical improvement in pCR rate for the identical lapatinib-containing regimen. We address differences in the two trials that may account for discordant conclusions. However, we use the FDA meta-analysis to show that there is no discordance at all between the observed pCR difference in NeoALTTO and the observed HR in ALTTO. This underscores the importance of appropriately modeling the two endpoints when designing clinical trials. The I-SPY 2/3 neoadjuvant trials exemplify this approach.
authors.affiliation: University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Angela
authors.initials: A
authors.lastname: DeMichele
authors.affiliation: University of Minnesota, Minneapolis, Minnesota.
authors.forename: Douglas
authors.initials: D
authors.lastname: Yee
authors.affiliation: University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Donald A
authors.initials: DA
authors.lastname: Berry
authors.affiliation: Loyola University Medical Center, Maywood, Illinois.
authors.forename: Kathy S
authors.initials: KS
authors.lastname: Albain
authors.affiliation: Buck Institute for Research on Aging, Novato, California.
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Benz
authors.affiliation: Mayo Clinic, Rochester, Minnesota.
authors.forename: Judy
authors.initials: J
authors.lastname: Boughey
authors.affiliation: University of California, San Francisco, San Francisco, California.
authors.forename: Meredith
authors.initials: M
authors.lastname: Buxton
authors.affiliation: British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
authors.forename: Stephen K
authors.initials: SK
authors.lastname: Chia
authors.affiliation: University of California, San Francisco, San Francisco, California.
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Chien
authors.affiliation: Oregon Health and Science University, Portland, Oregon.
authors.forename: Stephen Y
authors.initials: SY
authors.lastname: Chui
authors.affiliation: University of Pennsylvania, Philadelphia, Pennsylvania.
authors.forename: Amy
authors.initials: A
authors.lastname: Clark
authors.affiliation: Inova Fairfax Hospital Cancer Center, Fairfax, Virginia.
authors.forename: Kirsten
authors.initials: K
authors.lastname: Edmiston
authors.affiliation: University of Colorado Denver, Denver, Colorado.
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Elias
authors.affiliation: University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Andres
authors.initials: A
authors.lastname: Forero-Torres
authors.affiliation: Mayo Clinic, Rochester, Minnesota.
authors.forename: Tufia C
authors.initials: TC
authors.lastname: Haddad
authors.affiliation: University of Texas Southwestern, Dallas, Texas.
authors.forename: Barbara
authors.initials: B
authors.lastname: Haley
authors.affiliation: Mayo Clinic, Rochester, Minnesota.
authors.forename: Paul
authors.initials: P
authors.lastname: Haluska
authors.affiliation: University of California, San Francisco, San Francisco, California.
authors.forename: Nola M
authors.initials: NM
authors.lastname: Hylton
authors.affiliation: Georgetown University Medical Center, Washington, DC.
authors.forename: Claudine
authors.initials: C
authors.lastname: Isaacs
authors.affiliation: Swedish Cancer Institute, Seattle, Washington.
authors.forename: Henry
authors.initials: H
authors.lastname: Kaplan
authors.affiliation: University of Washington, Seattle, Washington.
authors.forename: Larissa
authors.initials: L
authors.lastname: Korde
authors.affiliation: Emory University, Atlanta, Georgia.
authors.forename: Brian
authors.initials: B
authors.lastname: Leyland-Jones
authors.affiliation: Mayo Clinic, Rochester, Minnesota.
authors.forename: Minetta C
authors.initials: MC
authors.lastname: Liu
authors.affiliation: University of California, San Francisco, San Francisco, California.
authors.forename: Michelle
authors.initials: M
authors.lastname: Melisko
authors.affiliation: H. Lee Moffitt Cancer Center, Tampa, Florida.
authors.forename: Susan E
authors.initials: SE
authors.lastname: Minton
authors.affiliation: University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Stacy L
authors.initials: SL
authors.lastname: Moulder
authors.affiliation: University of Chicago, Chicago, Illinois.
authors.forename: Rita
authors.initials: R
authors.lastname: Nanda
authors.affiliation: University of Chicago, Chicago, Illinois.
authors.forename: Olufunmilayo I
authors.initials: OI
authors.lastname: Olopade
authors.affiliation: QuantumLeap Healthcare Collaborative, San Francisco, California.
authors.forename: Melissa
authors.initials: M
authors.lastname: Paoloni
authors.affiliation: University of California, San Francisco, San Francisco, California.
authors.forename: John W
authors.initials: JW
authors.lastname: Park
authors.affiliation: University of California, San Diego, San Diego, California.
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Parker
authors.affiliation: Gemini Group Ann Arbor, Michigan.
authors.forename: Jane
authors.initials: J
authors.lastname: Perlmutter
authors.affiliation: George Mason University, Fairfax County, Virginia.
authors.forename: Emanuel F
authors.initials: EF
authors.lastname: Petricoin
authors.affiliation: University of California, San Francisco, San Francisco, California.
authors.forename: Hope
authors.initials: H
authors.lastname: Rugo
authors.affiliation: University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Fraser
authors.initials: F
authors.lastname: Symmans
authors.affiliation: University of Southern California, Los Angeles, California.
authors.forename: Debasish
authors.initials: D
authors.lastname: Tripathy
authors.affiliation: University of California, San Francisco, San Francisco, California.
authors.forename: Laura J
authors.initials: LJ
authors.lastname: van't Veer
authors.affiliation: University of Arizona Cancer Center, Tucson, Arizona.
authors.forename: Rebecca K
authors.initials: RK
authors.lastname: Viscusi
authors.affiliation: University of California, San Diego, San Diego, California.
authors.forename: Anne
authors.initials: A
authors.lastname: Wallace
authors.affiliation: University of California, San Francisco, San Francisco, California.
authors.forename: Denise
authors.initials: D
authors.lastname: Wolf
authors.affiliation: Buck Institute for Research on Aging, Novato, California.
authors.forename: Christina
authors.initials: C
authors.lastname: Yau
authors.affiliation: University of California, San Francisco, San Francisco, California. Laura.Esserman@ucsfmedctr.org.
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Esserman
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D016896:Treatment Outcome